Crizotinib received U.S. Food and Drug Administration (FDA) registration in 2011 for the treatment of non-small-cell lung cancer (NSCLC) with ALK gene rearrangement in second and subsequent lines of treatment and was approved as a first-line treatment by the FDA in 2013 [16,22]; Table 2. Here, ALK is linked to non-small cell lung carcinoma.